{
  "docId": "019de072-75de-708e-aad9-55788df6c953",
  "docSlug": "5188528054c3088b6a98b04815eb3ce3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 40,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Slide compares pricing dynamics (waterfall chart) and patient segmentation (concentric circles) for Ultomiris vs Soliris.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-75de-708e-aad9-55788df6c953/25",
  "deckHref": "/decks/019de072-75de-708e-aad9-55788df6c953",
  "deckJsonHref": "/decks/019de072-75de-708e-aad9-55788df6c953.json",
  "deckAnchorHref": "/decks/019de072-75de-708e-aad9-55788df6c953#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.52,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Ultomiris approved for gMG in US; EU and Japan H2",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be53b2e4-d573-4a5a-bab8-1a214c8317e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Ultomiris vs. Soliris US pricing dynamics",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b39fcac2-7e64-4774-91fb-11a08e1a8e5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.53,
        "y": 0.26
      },
      "kind": "diagram",
      "text": "Ultomiris: expanding in gMG",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4853f1a-ab27-4e78-a809-fd4a2c1467d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "list",
      "text": "Ultomiris established standard of care in PNH; COVID-19 impact on aHUS; Anticipate rapid gMG conversion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2319ed77-c126-4d37-b81b-a3c6da841ccb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Westerberg E, Brain and behavior. 2020 Nov;10(11):e01819; PNH = paroxysmal nocturnal haemoglobinuria; aHUS = atypical haemolytic uraemic syndrome; gMG = generalised myasthenia gravis; NMOSD = neuromyelitis optica spectrum disorder; IST = immunosuppressive therapy; NME = new molecular entity.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29c7c34f-9ae3-42d1-a5ae-e0499a9cb44d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "gMG approval accelerates Ultomiris growth rate H2 2022",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2a2f6cb-7286-46b4-9d4a-03ab9ad8ed39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Durable C5 franchise",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b4832d0-d6ae-458b-a4e8-5e2032941fcb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "3cef47ae-a2cc-4674-aefd-80b8bc613768",
      "evidence": "title/action-title: gMG approval accelerates Ultomiris growth rate H2 2022",
      "confidence": 0.7
    },
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "4a79fc1a-968b-4b5a-98f1-d3c7f28b85a7",
      "evidence": "chart/waterfall: Ultomiris vs. Soliris US pricing dynamics",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}